The newly launched biotech is equipped with rights to a trio of weight loss medicines licensed from China-based Sciwind ...

Maridebart cafraglutide, a novel injectable GIP receptor antagonist/GLP-1 receptor agonist, reduced body weight by ...

New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent ...

A systematic review of randomized controlled trials (RCTs) assessed the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for obesity in adults without ...

27, 2024 — A recent trial finds an injection given during some asthma and COPD attacks is more effective than the current treatment ... Obesity has been linked to a wide array of health problems ...

For the first time in a decade, U.S. obesity rates have begun to decline, raising hopes that the nation may be turning a ...

Weight-loss treatments are on the cusp of a revolution, and could benefit large numbers of Indians after the main patent ...

In a surprising turn, obesity rates in the United States have decreased for the first time in more than a decade, according to a study published in the Journal of JAMA Health Forum. The study ...

I analyze Scholar Rock's promising Phase 3 results for SMA drug, but warn of financial challenges and recommend a Hold rating ...

The history of breakthrough weight loss medicines is riddled with tragic results. Based on the histories of phen-fen and rimonabant, many are concerned about GLP-1 agonists. Notably, the mechanisms of ...

In a first, scientists at the World Health Organisation (WHO) have endorsed a new class of medicines known ... doctors prescribed it off-label for obesity, sparking a social media frenzy and supply ...

Shares in the company dived after a new anti-obesity treatment missed expectations in a study, denting its chances of becoming the company’s next blockbuster weight loss drug. RFK Jr. hit an ...